Stock Ratings / Health Care / OPK / insiders

SLN (34) SNDX (31) LBRX (43) VSTM (24) ⌘ Pro Terminal →

OPKO Health Inc. (OPK) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.66 +2.47% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

OPKO Health Inc. (OPK) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.24B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OPK)Realized 20D OHLCV Swing Band: ±11.7%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

OPK Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (OPK)

No recent open-market Form 4 cluster sales or emergency dumps flagged on OPK. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OPK)

✓Walkthrough of OPK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

OPK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +46.90%▲ ASCENDING CHANNEL

2026-10-30O $1.66H $1.69L $1.64C $1.66VOL 2.15M

RES: $1.78SUP: $1.33SMA50: $1.56SMA200: $1.34

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OPK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OPK Butterfly Map → + Track OPK →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -14.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on OPK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OPK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for OPK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OPK)

Health Care Rank #663 of 1016 ⚔️ SLN vs OPK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OPK vs. SLN, SNDX, LBRX, VSTM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, OPKO Health Inc. (OPK) ranks #663 by composite RQD confidence (39/100, grade D-) and #333 by equity capitalization ($1.24B). Within this direct 5-issuer industry benchmark cohort, OPK leads on earnings valuation at N/A trailing P/E, while LBRX leads on capital efficiency and profitability with -8.4% ROIC and — gross margin. LBRX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with OPK at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
OPK ACTIVE OPKO Health Inc.	D-	39/100	—	33.9%	-10.2%	+2.47%	$1.24B	Benchmark Subject
SLN Silence Therapeutics Plc American Depository Share	E	34/100	—	61.5%	-35.0%	+0.46%	$1.23B	/sln-vs-opk →
SNDX Syndax Pharmaceuticals Inc.	E	31/100	—	—	-35.0%	-1.19%	$1.26B	/sndx-vs-opk →
LBRX LB Pharmaceuticals Inc	D-	43/100	—	—	-8.4%	+0.80%	$1.30B	/lbrx-vs-opk →
VSTM Verastem Inc.	E	24/100	—	—	-35.0%	-1.78%	$1.17B	/vstm-vs-opk →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000944809

In its most recent audited fiscal period (FY2025, filed 2025-12-31), OPKO Health Inc. (OPK) reported GAAP revenue of $606.9M (-14.9% vs. FY2024 revenue of $713.1M , and -29.7% cumulative change since FY2023) , GAAP net income of -$225.68B, operating cash flow of -$178.5M, and free cash flow of -$178.5M (+2.7% YoY). On the balance sheet, OPK closed FY2025 with $1.93B in total assets against $2.3M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$606.9M	-$225.68B	-$178.5M	-$178.5M	$1.93B	$2.3M
FY2024 (FY)	2024-12-31	$713.1M	-$53.22B	-$183.5M	-$183.5M	$2.20B	$3.0M
FY2023 (FY)	2023-12-31	$863.5M	-$188.86B	-$28.2M	-$28.2M	—	—

3. OPK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OPK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, OPKO Health Inc. (NASDAQ: OPK) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.66 (+2.47% 1D, market cap $1.24B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OPK ranks #663 in composite RQD confidence.

How does OPK compare to SLN and SNDX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OPK carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 33.9%, and ROIC of -10.2%. By comparison, SLN (Silence Therapeutics Plc American Depository Share) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $1.23B) and SNDX (Syndax Pharmaceuticals Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $1.26B). Among the 5-stock peer group, OPK leads on earnings multiple (N/A) while LBRX leads on capital efficiency (-8.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OPK?

Per OPK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000944809), OPKO Health Inc. generated $606.9M in revenue (-14.9% YoY), -$225.68B in net income, and -$178.5M in free cash flow against $1.93B in total assets and $2.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OPK trading relative to its 50-day, 200-day, and 52-week technical levels?

OPK last traded at $1.66 (+2.47% on volume of 1,976,749 shares), positioning the stock +6.41% above its 50-day simple moving average ($1.56) and +23.88% above its 200-day simple moving average ($1.34). Across its 52-week range of $0.98 to $1.77, OPK sits at the 86.1% percentile with a 14-day RSI of 58.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.7% ($1.47 to $1.85).

OPK Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are OPK insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies OPK leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: OPK RQD Cockpit OPK 12M Forecast OPK Earnings & Move OPK Dividends & DRIP OPK Insiders & 13F OPK Whale Options OPK Profit Sankey OPK News & Why